Abstract
144P Preliminary safety and efficacy of iruplinalkib after chemoradiotherapy (CRT) in ALK/ROS1+ unresectable non-small cell lung cancer (NSCLC): Part 1 results from the INNOVATION study
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
